Moreover, NLR decrease during treatment was a significant predictor of overall survival on multivariate analysis [HR 0.380; 95% CI 0.18–0.80)] after adjustment for age, ECOG performance status, extent of resection, IDH mutation status, grade IV tumor, and baseline and time-weighted mean dexamethasone dose (53). This evidence concerns the gene IDH1 and neoplasm.